Milton Packer

Last updated

Milton Packer (b. ca 1951) is an American cardiologist who is known for his clinical research concerning heart failure.

Contents

Early life and education

Milton Packer was born in the United States to Holocaust survivors who were saved from the Vilna ghetto by Karl Plagge. He grew up in Philadelphia, where his father worked as a tailor. He was politically active in the 1960s. [1]

He earned his undergraduate degree at Pennsylvania State University in 1971 and his medical degree from Jefferson Medical College in Philadelphia in 1973 [2] when he was 22 years old. [1] He completed his residency at Albert Einstein College of Medicine in New York City, where Edmund Sonnenblick was working, and a fellowship in cardiology at Mount Sinai School of Medicine in New York, where Richard Gorlin was conducting research. [1]

Academic career

In 1979 he was made an assistant professor at Mount Sinai, was promoted to associate professor in 1983, and was made a professor in 1988. In 1992 he moved to Columbia University and was made the Dickinson Richards Professor of Medicine. [2] Columbia has recruited him with an invitation to build a clinical and research program in heart failure, and he in turn recruited faculty who had a strong interest in both; members of the group could come up with a hypothesis about heart failure while treating a patient, and that doctor or another member of the team would begin researching it the same day. [1]

In 2004, he moved to University of Texas Southwestern Medical Center as a trailing spouse. [1] He was offered a named professorship and the opportunity to set up a center within the college focused on teaching clinical research and supporting career development for doctors who wanted to pursue a career in clinical research. The center brought biostaticians, who had been in the public health department, together with physicians from many branches of medicine, with the goal of spreading the appreciation for rigorous statistical design of clinical research and making statistical expertise more widely available in the college. [3] Packer earned an NIH Clinical and Translational Science Award in 2007 to support these efforts. [4]

In 2015 he was appointed a distinguished scholar at the Baylor University Medical Center at Dallas. [5]

Research

Along with practicing cardiology, he spent the first part of his career doing small clinical research studies trying to better understand the pathology of heart failure. [3]

In 1992 he published a paper on a neurohormonal hypothesis to explain heart failure that synthesized ideas that were percolating at the time; the paper made him known as the father of that idea. [1] [6]

In 1986 he joined the Cardiac and Renal Drugs Advisory Committee at the FDA, [2] an event that he said was life-changing. [3]

"The pivotal event for me was my appointment as a member of the cardiorenal advisory committee for the Food and Drug Administration. The Food and Drug Administration is the country's most valuable resource for clinical data, clinical research design, and clinical research analysis. The people who are there receive voluminous amounts of data about drugs in development and drugs already on the market and are challenged with how to find the "truth" in the data and how to translate that truth into decisions about public health. This is an unbelievably hard job and a terribly important responsibility. If the FDA makes a mistake, there is a potential for an enormous amount of suffering; if they do the right thing, there is a real opportunity for an enormous number of lives to be saved and the quality of lives to be improved. They have, within their community, developed clinical trial methodology to an unbelievably high standard, the highest standard in the world." [3]

After this he started getting involved running large multi-center clinical trials for heart failure drugs, several of which were landmark studies in the care of heart failure. [3]

He was principal investigator on the REFLECT trial for flosequinan which ran from 1987-1989 and the following PROFILE trial from 1991-1994. He was PI on a study of amlodipine that ran from 1987-1989 and the following PRAISE trial from 1992-1995 and PRAISE 2 from 1996-1999; the PROMISE trial for milrinone 1988-1990; the ATLAS trial for lisinopril from 1993-1997; the PRECISE trial for carvedilol from 1993-1995 and the following COPERNICUS trial from 1997-2002; the ENABLE trial (1999-2001) and REACH-1 trial (1997-2003) for bosentan; the OVERTURE trial (1999-2002) for omapatrilat; REVIVE I and II (2001-2006) for levosimendan; and the TRUE-AHF trial of ularitide that started in 2013. He also chaired the steering committee for the RADIANCE trial from 1989-1992 which studied the use of digoxin in people who were also treated with ACE inhibitors and chaired the steering committee for the RENEWAL trial (1999-2002) for etanercept. [2] He was also the co-PI of the PARADIGM-HF trial that led to the approval of valsartan/sacubitril. [7] [8]

The PROFILE trial had negative results; it was terminated early in 1993 due to increased mortality in the drug arm of the trial. Packer was the lead author of the conference abstract in which topline results were presented. The abstract promised that data and analysis would be forthcoming in a future paper; as of 2001 no such paper had been published. [9] Similarly, the REACH-1 trial had negative results and was terminated early, and the preliminary results were presented at a conference by Packer, with no full publication following as of 2001, leaving the field without insight into why the drug caused harm at the dosage given in that trial. [9] Results of both trials were published in 2017, with an explanation about the delay. [10] [11]

The success of the PARADIGM-HF trial was a great satisfaction for him, as it validated the neurohormonal hypothesis; an earlier effort with omapatrilat had failed due to side effects caused by the drug candidate. [1]

He was a founding member and former President of Heart Failure Society of America. [2] His research on the treatment of heart failure led to him being awarded the Lewis Katz lifetime achievement award in cardiovascular research. [12] [1]

Related Research Articles

<span class="mw-page-title-main">Coronary artery disease</span> Reduction of blood flow to the heart muscle due to plaque buildup in the hearts arteries

Coronary artery disease (CAD), also called coronary heart disease (CHD), ischemic heart disease (IHD), myocardial ischemia, or simply heart disease, involves the reduction of blood flow to the heart muscle due to build-up of atherosclerotic plaque in the arteries of the heart. It is the most common of the cardiovascular diseases. Types include stable angina, unstable angina, myocardial infarction, and sudden cardiac death. A common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw. Occasionally it may feel like heartburn. Usually symptoms occur with exercise or emotional stress, last less than a few minutes, and improve with rest. Shortness of breath may also occur and sometimes no symptoms are present. In many cases, the first sign is a heart attack. Other complications include heart failure or an abnormal heartbeat.

<span class="mw-page-title-main">Alcohol and cardiovascular disease</span> Effects of alcohol consumption on cardiovascular health

Excessive alcohol intake is associated with an elevated risk of alcoholic liver disease (ALD), heart failure, some cancers, and accidental injury, and is a leading cause of preventable death in industrialized countries. Some studies have suggested that one drink per day may have cardiovascular benefits. However, these studies are controversial, and the common view is that no level of alcohol consumption improves health. There is far more evidence for the harmful effects of alcohol than for any beneficial effects. It is also recognized that the alcohol industry may promote the unsubstantiated benefits of moderate drinking.

<span class="mw-page-title-main">Bosentan</span> Chemical compound

Bosentan, sold under the brand name Tracleer and Safebo among others, is a dual endothelin receptor antagonist medication used in the treatment of pulmonary artery hypertension (PAH).

<span class="mw-page-title-main">Moxonidine</span> Chemical compound

Moxonidine (INN) is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction. It is also a growth hormone releaser. It is manufactured by Solvay Pharmaceuticals under the brand name Physiotens & Moxon.

<span class="mw-page-title-main">Hypertensive heart disease</span> Medical condition

Hypertensive heart disease includes a number of complications of high blood pressure that affect the heart. While there are several definitions of hypertensive heart disease in the medical literature, the term is most widely used in the context of the International Classification of Diseases (ICD) coding categories. The definition includes heart failure and other cardiac complications of hypertension when a causal relationship between the heart disease and hypertension is stated or implied on the death certificate. In 2013 hypertensive heart disease resulted in 1.07 million deaths as compared with 630,000 deaths in 1990.

<span class="mw-page-title-main">Ventricular assist device</span> Medical device to assist or replace a heart

A ventricular assist device (VAD) is an electromechanical device for assisting cardiac circulation, which is used either to partially or to completely replace the function of a failing heart. The function of a VAD differs from that of an artificial cardiac pacemaker in that a VAD pumps blood, whereas a pacemaker delivers electrical impulses to the heart muscle. Some VADs are for short-term use, typically for patients recovering from myocardial infarction (heart attack) and for patients recovering from cardiac surgery; some are for long-term use (months to years to perpetuity), typically for patients with advanced heart failure.

<span class="mw-page-title-main">Ivabradine</span> Heart medication

Ivabradine, sold under the brand name Procoralan among others, is a medication, which is a pacemaker current (If) inhibitor, used for the symptomatic management of heart-related chest pain and heart failure. Patients who qualify for use of Ivabradine for coronary heart failure are patients who have symptomatic heart failure, with reduced ejection volume, and heart rate at least 70 bpm, and the condition not able to be fully managed by beta blockers.

<span class="mw-page-title-main">Flosequinan</span> Chemical compound

Flosequinan is a quinolone vasodilator that was discovered and developed by Boots UK and was sold for about a year under the trade name Manoplax. It had been approved in 1992 in the US and UK to treat people with heart failure who could not tolerate ACE inhibitors or digitalis.

<span class="mw-page-title-main">Dapagliflozin</span> Diabetes medication

Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease.

<span class="mw-page-title-main">European Society of Cardiology</span> Non-profit professional association

The European Society of Cardiology (ESC) is an independent non-profit, non-governmental professional association that works to advance the prevention, diagnosis and management of diseases of the heart and blood vessels, and improve scientific understanding of the heart and vascular system. This is done by:

Management of heart failure requires a multimodal approach. It involves a combination of lifestyle modifications, medications, and possibly the use of devices or surgery.

Cardiorenal syndrome (CRS) is an umbrella term used in the medical field that defines disorders of the heart and kidneys whereby "acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other". The kidney and the heart are compared to a marriage that has "bumps" in the road, some may even say it can come to an end. The heart and kidney play vital functions that contribute to the wellbeing of the body in a healthy person. When one of these organs fail, the other subsequently fails as well, like a domino affect. The heart and the kidneys are involved in maintaining hemodynamic stability and organ perfusion through an intricate network. Patients who have renal failure first may be hard to determine if heart failure is concurrent. These two organs communicate with one another through a variety of pathways in an interdependent relationship. In a 2004 report from National Heart, Lung and Blood Institute, CRS was defined as a condition where treatment of congestive heart failure is limited by decline in kidney function. This definition has since been challenged repeatedly but there still remains little consensus over a universally accepted definition for CRS. At a consensus conference of the Acute Dialysis Quality Initiative (ADQI), the CRS was classified into five subtypes primarily based upon the organ that initiated the insult as well as the acuity of disease.

<span class="mw-page-title-main">Philip Poole-Wilson</span>

Philip Alexander Poole-Wilson FRCP, FESC, FACC, FMedSci was a British academic cardiologist of international reputation who had particular interest in the management of heart failure. His research helped to identify the cellular mechanisms behind heart failure and was also important in improving treatment for patients. He was instrumental in raising the profile of heart failure as a major public health problem.

<span class="mw-page-title-main">Andrew Stewart Coats</span> Australian–British academic cardiologist (born 1958)

Andrew Justin Stewart Coats is an Australian–British academic cardiologist who has particular interest in the management of heart failure. His research suggested exercise training as a more effective treatment for chronic heart failure. He is known for putting forward the "muscle hypothesis" of heart failure. In addition to this, Coats is a fundraiser, university administrator, and inventor. His Imperial College patents have formed the basis of companies specialising in the treatment of cachexia.

Frederick A. Masoudi is an American cardiologist with expertise in cardiovascular outcomes research, clinical registries and quality measurement.

<span class="mw-page-title-main">Sacubitril/valsartan</span> Combination medication

Sacubitril/valsartan, sold under the brand name Entresto, is a fixed-dose combination medication for use in heart failure. It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan. The combination is sometimes described as an "angiotensin receptor-neprilysin inhibitor" (ARNi). In 2016, the American College of Cardiology/American Heart Association Task Force recommended it as a replacement for an ACE inhibitor or an angiotensin receptor blocker in people with heart failure with reduced ejection fraction.

The Q-Symbio study was an international multi-center clinical trial that was reported in the Journal of the American College of Cardiology: Heart Failure in September 2014.

<span class="mw-page-title-main">Stefan D. Anker</span>

Stefan D. Anker is Head of Field “Tissue Homeostasis and Cachexia" at Charité University, Berlin, Germany. Previously, he was Professor of Innovative Clinical Trials at University Medical Center Göttingen in Germany. The main focus of the Innovative Clinical Trials department was research in the field of chronic heart failure, including the development and clinical testing of new therapies.

Douglas L. Mann is an American physician. He is currently the Lewin Distinguished Professor in Cardiovascular Diseases and professor of medicine, cell biology and physiology at Washington University School of Medicine in St. Louis.

<span class="mw-page-title-main">Roberto Ferrari (cardiologist)</span> Italian Cardiologist

Roberto Ferrari is an Italian cardiologist who currently holds the position of Emeritus Professor at the University of Ferrara, where besides he was the chair of the Cardiology in the School of Medicine until the 2019-2020 academic year.

References

  1. 1 2 3 4 5 6 7 8 Nicholls, Mark (1 June 2016). "CardioPulse Articles: Pioneers in cardiovascular medicine -- Milton Packer MD". European Heart Journal. 37 (21): 1633–41. doi: 10.1093/eurheartj/ehw169 . PMID   27252477.
  2. 1 2 3 4 5 "Milton Packer CV" (PDF). FDA Cardiovascular and Renal Drugs Advisory Committee. Retrieved 6 August 2017.
  3. 1 2 3 4 5 Packer, M (November 2004). "Milton Packer, MD, Director, Center for Biostatistics and Clinical Science at UT Southwestern". Journal of Investigative Medicine. 52 (7): 421–4. doi:10.1136/jim-52-07-01. PMID   15651258.
  4. ↑ "Press release: UT Southwestern earns $34M NIH grant to foster patient-oriented research". UT Southwestern via EurekAlert!. September 18, 2007.
  5. ↑ "Press release: Cardiologist Milton Packer, M.D., Joins Baylor University Medical Center at Dallas". Baylor Scott & White Health. December 3, 2015.
  6. ↑ Packer, M (July 1992). "The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure". Journal of the American College of Cardiology. 20 (1): 248–54. doi:10.1016/0735-1097(92)90167-L. PMID   1351488.
  7. ↑ Husten, Larry (March 31, 2014). "Novartis Trial Was Stopped Early Because Of A Significant Drop In Cardiovascular Mortality". Forbes.
  8. ↑ McMurray, JJ; Packer, M; Desai, AS; Gong, J; Lefkowitz, MP; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR; PARADIGM-HF Investigators and, Committees. (11 September 2014). "Angiotensin-neprilysin inhibition versus enalapril in heart failure". The New England Journal of Medicine. 371 (11): 993–1004. doi:10.1056/NEJMoa1409077. hdl: 10993/27659 . PMID   25176015.
  9. 1 2 van Veldhuisen, DJ; Poole-Wilson, PA (August 2001). "The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure". International Journal of Cardiology. 80 (1): 19–27. doi:10.1016/S0167-5273(01)00447-8. PMID   11532543.
  10. ↑ Packer, M; Pitt, B; Rouleau, JL; Swedberg, K; DeMets, DL; Fisher, L (June 2017). "Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years". JACC: Heart Failure. 5 (6): 399–407. doi: 10.1016/j.jchf.2017.03.003 . PMID   28501522.
  11. ↑ Packer, M; McMurray, JJV; Krum, H; Kiowski, W; Massie, BM; Caspi, A; Pratt, CM; Petrie, MC; DeMets, D; Kobrin, I; Roux, S; Swedberg, K; ENABLE Investigators and, Committees. (May 2017). "Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials". JACC: Heart Failure. 5 (5): 317–326. doi: 10.1016/j.jchf.2017.02.021 . hdl: 10536/DRO/DU:30157497 . PMID   28449795.
  12. ↑ "Profile: Dr. Milton Packer". Baylor Scott & White Health. Retrieved 6 August 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.